Drug Profile

CD 377

Alternative Names: CD-377

Latest Information Update: 08 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cidara Therapeutics
Developer Merck & Co
Class Antivirals; Drug conjugates; Immunoconjugates; Immunoglobulin Fc fragments
Mechanism of Action Antibody-dependent cell cytotoxicity

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Influenza virus infections

Most Recent Events

07 Jan 2026 Cidara Therapeutics has been acquired and merged into Merck & Co
28 Apr 2025 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in USA (IM)
28 Jan 2025 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in USA (IV)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com